Van Damme P, Vranckx R, Safary A, André F E, Meheus A
Department of Epidemiology and Community Medicine, University of Antwerp, Belgium.
Am J Med. 1989 Sep 4;87(3A):26S-29S. doi: 10.1016/0002-9343(89)90527-5.
Mentally handicapped clients in institutions are at high risk for hepatitis B virus (HBV) infection. In 1985, 770 mentally handicapped residents from four institutions in the Antwerp area were screened for HBV markers. The prevalence of hepatitis B surface antigen was 10.3 percent (range, 6.1 to 15.2 percent); 42.3 percent (range, 11.5 to 60.1 percent) had antibodies to hepatitis B surface antigen and the hepatitis B core antigen. In 1986, 275 seronegative mentally handicapped residents were vaccinated intramuscularly in the deltoid region with 20 micrograms (1.0 ml) of a recombinant deoxyribonucleic acid yeast-derived hepatitis B vaccine (Engerix-B, SmithKline Biologicals, Rixensart, Belgium) on a zero-, one-, six-month schedule. Serum samples were collected at Months 1, 2, 7, 12, and 24 and were tested for HBV markers by radioimmunoassay. The seroconversion rates for hepatitis B surface antigen antibodies were 39 percent at Month 1 (geometric mean concentration, 6.4 IU/liter), 82 percent at Month 2 (geometric mean concentration, 23.4 IU/liter), 97 percent at Month 7 (geometric mean concentration, 1,034 IU/liter), and 96 percent at Month 12 (geometric mean concentration, 269 IU/liter). Among the 214 residents evaluated at Month 12, 69 percent had hepatitis B surface antigen antibody levels greater than 100 IU/liter (geometric mean concentration, 603 IU/liter). No significant adverse reactions were observed. Within the first seven months of observation, HBV infection was detected in eight of 271 subjects (estimated annual incidence of 5 percent). During this period, none of the clients developed clinical hepatitis or showed biochemical evidence of liver damage. Between eight and 24 months, no additional HBV infections were detected. These data can be compared with an annual incidence of HBV infection of 8.7 percent in a historical cohort of mentally handicapped residents in one of the four institutions.
福利院中的智力障碍者感染乙型肝炎病毒(HBV)的风险很高。1985年,对安特卫普地区四家福利院的770名智力障碍者进行了HBV标志物筛查。乙肝表面抗原的患病率为10.3%(范围为6.1%至15.2%);42.3%(范围为11.5%至60.1%)的人有乙肝表面抗原和乙肝核心抗原抗体。1986年,275名血清学阴性的智力障碍者在三角肌区域进行肌肉注射,按照0、1、6月的接种程序,接种20微克(1.0毫升)重组脱氧核糖核酸酵母衍生乙肝疫苗(Engerix - B,史克必成生物制品公司,比利时里克森萨特)。在第1、2、7、12和24个月采集血清样本,并用放射免疫分析法检测HBV标志物。乙肝表面抗原抗体的血清转化率在第1个月时为39%(几何平均浓度为6.4国际单位/升),第2个月时为82%(几何平均浓度为23.4国际单位/升),第7个月时为97%(几何平均浓度为1034国际单位/升),第12个月时为96%(几何平均浓度为269国际单位/升)。在第12个月评估的214名居民中,69%的人乙肝表面抗原抗体水平高于100国际单位/升(几何平均浓度为603国际单位/升)。未观察到明显的不良反应。在观察的前七个月内,271名受试者中有8人检测到HBV感染(估计年发病率为5%)。在此期间,没有患者出现临床肝炎或显示出肝损伤的生化证据。在8至24个月期间,未检测到其他HBV感染。这些数据可与四家福利院之一中一个历史队列的智力障碍居民的HBV年感染率8.7%进行比较。